Imagion to present at Switzer Small and Microcap Investor Day

Come along to Switzer Small & Micro Cap Investor Day Switzer Financial Group is pleased to bring you the Switzer Small & Micro Cap Investor Day on…


Business Update: Manufacturing Commences

Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to…


Notice of ceasing to be a substantial holder

Form 605, "Notice of ceasing to be a substantial holder", has been released to the ASX. Read Form 605.  


Oliver Steinbach, PhD, Appointed Vice President of Clinical and Regulatory Affairs

Imagion Biosystems announces the appointment of Oliver Steinbach, PhD, as Vice President of Clinical and Regulatory Affairs. Dr. Steinbach will serve as the…


Imagion Biosystems Appendix 4C - Quarterly

Imagion Biosystems has today released its Appendix 4C Quarterly Cash Flow Report and update on Company activities for the quarter ending 31 December 2019. Read…


Appointment of Vice President Clinical and Regulatory Affairs

Imagion Biosystems announces the appointment of Oliver Steinbach PhD to the position of Vice President Clinical and Regulatory Affairs. Read the announcement.


Appendix 3B — New Issue Announcement

"Appendix 3B New issue announcement" has been released by Imagion Biosystems. Read Appendix 3B New Issue Announcement.


Response to Price Query

Imagion Biosystems has announced the following Response to Price Query with the ASX. Read the Response to Price Query.


Response to ASX App 3Y Query

The following response to "Appendix 3Y — Change of Director's Interest Notice Query" has been announced. Read the response.


Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Imagion Biosystems has released "Notice Pursuant to Section 708A(5)(e) of the Corporations Act." Read the notice.